Sökning: onr:"swepub:oai:prod.swepub.kib.ki.se:144373837" >
FIRST LINE TREATMEN...
FIRST LINE TREATMENT WITH CONVENTIONAL SYNTHETIC DISEASE MODIFYING ANTIRHEUMATIC DRUGS IN RHEUMATOID ARTHRITIS: A MULTINATIONAL POPULATION-BASED COHORT FROM 14 REAL WORLD HEALTHCARE DATABASES AND 9 COUNTRIES - REALITY VERSUS GUIDELINES
- Artikel/kapitelEngelska2020
Förlag, utgivningsår, omfång ...
Nummerbeteckningar
-
LIBRIS-ID:oai:prod.swepub.kib.ki.se:144373837
-
http://kipublications.ki.se/Default.aspx?queryparsed=id:144373837URI
-
https://doi.org/10.1136/annrheumdis-2020-eular.3131DOI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:vet swepub-contenttype
-
Ämneskategori:kon swepub-publicationtype
Anmärkningar
-
Treatment guidelines recommend early initiation of csDMARDs following diagnosis of rheumatoid arthritis (RA), with methotrexate (MTX) as first-line therapy. Scarce evidence exists on adherence to this guidanceObjectives:To characterize first-line csDMARD treatment during the first year following an RA diagnosis.Methods:14 real world databases (3 Primary care, 6 primary/secondary care records, 5 claims) from 9 countries were included, all mapped to the OMOP common data model.Patients were included on the earliest event of: 1st diagnosis of RA or 1st DMARD prescription with an RA diagnosis within 30 days. Patients were >18 years-old, required 1+ year pre-index data, and at least 1-year follow-up. Study period covered 2000-2018. Previous users of DMARDs or non-RA inflammatory arthritis history were excluded. Only MTX, Hydroxychloroquine (HCQ), Sulfasalazine (SSZ) and Leflunomide (LEF) were available in all databases.Results:We identified 323,547 eligible participants. Large variation was observed internationally (Figure 1). MTX as first-line monotherapy ranged from 33.3% to 74.5%, and in combination with HCQ from 2.1% to 6.7%. Three additional csDMARDs were used as first-line: HCQ in 10.1% to 30.2%, SSZ in 0.9% to 28.7%, and LEF in 1.8% to 15.2%.Figure 1.First line csDMARD treatment during 1yr from first observed RA diagnosisConclusion:We report wide heterogeneity of first-line csDMARDs regimens internationally. Despite recommendations for MTX to be first line therapy, data suggest that a large proportion of patients receive alternative csDMARD.Disclosure of Interests: :Anthony G Sena Shareholder of: J&J shares, Grant/research support from: Full-time employment salary from Janssen, Consultant of: Full-time employment salary from Janssen, Employee of: Janssen employee, Paid instructor for: Janssen employee, Speakers bureau: Janssen employee, Denis Granados: None declared, Nigel Hughes Shareholder of: J&J shares, Grant/research support from: Full-time employment salary from Janssen, Consultant of: Janssen employee, Employee of: Janssen employee, Paid instructor for: Janssen employee, Speakers bureau: Janssen employee, WALID FAKHOURI Shareholder of: E Lilly Shares, Employee of: Eli Lilly and Company, Antje Hottgenroth Shareholder of: Eli Lilly shares, Employee of: Lilly Deutschland GmbH, Raivo Kolde: None declared, Sulev Reisberg: None declared, Carmen Olga Torre: None declared, Talita Duarte-Salles: None declared, Yesika Díaz: None declared, Jose Felipe Golib-Dzib Grant/research support from: Full-time employment salary from Janssen, Employee of: Yes, Janssen employee, Paid instructor for: Janssen Employee, Speakers bureau: Janssen Employee, Emily S. Brouwer Shareholder of: J&J shares, Takeda shares, Grant/research support from: Full-time employment salary from Janssen, Consultant of: Janssen employee, Employee of: Janssen employee, Paid instructor for: Janssen Employee, Speakers bureau: Janssen Employee, Edward Burn: None declared, Jennifer Lane: None declared, David Vizcaya Employee of: Bayer, Sara Bruce Wirta Employee of: Janssen-Cilag Sweden AB, Marcel de Wilde: None declared, Katia Verhamme: None declared, Peter Rijnbeek: None declared, Elke Theander Employee of: Janssen-Cilag Sweden AB, Katerina Chatzidionysiou Consultant of: AbbVie, Pfizer, Lilly., Daniel Prieto-Alhambra Grant/research support from: Professor Prieto-Alhambra has received research Grants from AMGEN, UCB Biopharma and Les Laboratoires Servier, Consultant of: DPA’s department has received fees for consultancy services from UCB Biopharma, Speakers bureau: DPA’s department has received fees for speaker and advisory board membership services from Amgen, Patrick Ryan: None declared
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Granados, D
(författare)
-
Hughes, N
(författare)
-
Fakhouri, W
(författare)
-
Hottgenroth, A
(författare)
-
Kolde, R
(författare)
-
Reisberg, S
(författare)
-
Torre, CO
(författare)
-
Duarte-Salles, T
(författare)
-
Diaz, Y
(författare)
-
Golib-Dzib, JF
(författare)
-
Brouwer, ES
(författare)
-
Burn, E
(författare)
-
Lane, J
(författare)
-
Vizcaya, D
(författare)
-
Wirta, SB
(författare)
-
De Wilde, M
(författare)
-
Verhamme, K
(författare)
-
Rijnbeek, P
(författare)
-
Theander, E
(författare)
-
Chatzidionysiou, KKarolinska Institutet
(författare)
-
Prieto-Alhambra, D
(författare)
-
Ryan, P
(författare)
-
Karolinska Institutet
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:ANNALS OF THE RHEUMATIC DISEASES: BMJ79, s. 327-3270003-49671468-2060
Internetlänk
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Sena, AG
-
Granados, D
-
Hughes, N
-
Fakhouri, W
-
Hottgenroth, A
-
Kolde, R
-
visa fler...
-
Reisberg, S
-
Torre, CO
-
Duarte-Salles, T
-
Diaz, Y
-
Golib-Dzib, JF
-
Brouwer, ES
-
Burn, E
-
Lane, J
-
Vizcaya, D
-
Wirta, SB
-
De Wilde, M
-
Verhamme, K
-
Rijnbeek, P
-
Theander, E
-
Chatzidionysiou, ...
-
Prieto-Alhambra, ...
-
Ryan, P
-
visa färre...
- Artiklar i publikationen
-
ANNALS OF THE RH ...
- Av lärosätet
-
Karolinska Institutet